Opko Health, Inc.

  • Health Care
  • Biotechnology: Pharmaceutical Preparations
  • www.opko.com
  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $859.62M
  • PE -22
  • Debt $540.48M
  • Cash $449.68M
  • EV $950.42M
  • FCF -$206.24M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$39.00M
EBIT-$147.76M
ROE-3%
ROA-7%
FCF-$206.24M
Equity$1.31B
Growth Stability1
PE-22.04
PEG-103.31
PB0.66
P/FCF-4.17
P/S1.25
Price/Cash0.52
Debt/Equity0.41
Debt/FCF-2.62
Net Margins-45%
Gross Margins32%
Op. Margins-21%
Earnings CAGR-0%
Sales Growth YoY-14%
Sales Growth QoQ-18%
Sales CAGR-3%
FCF CAGR0%
Equity CAGR-3%
Earnings Stability0
Earnings Growth YoY-17%
Earnings Growth QoQ-582%
Earnings CAGR 5Y0%
Sales CAGR 5Y-17%
FCF CAGR 5Y-0%
Equity CAGR 5Y-6%
Earnings CAGR 3Y-21%
Sales CAGR 3Y-21%
Equity CAGR 3Y-9%
Market Cap$859.62M
Revenue$689.41M
Assets$2.13B
Total Debt$540.48M
Cash$449.68M
Shares Outstanding671.58M
EV950.42M
Earnings Score6%
Moat Score5%
Safety Score66%
Final Score26%
Working Capital441.75M
Current Ratio2.49
Gross Profit$219.06M
Shares Growth 3y-2%
Equity Growth QoQ-4%
Equity Growth YoY5%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a speciality active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

SEC Filings

Direct access to Opko Health, Inc. (OPK) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Opko Health, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Opko Health, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -0%
Stability 0%
loading chart...

Opko Health, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Opko Health, Inc..

= -$2.1B
012345678910TV
fcf-$206M-$207M-$207M-$208M-$208M-$208M-$209M-$209M-$210M-$210M-$211M-$2.1B
DCF-$188M-$171M-$156M-$142M-$129M-$118M-$107M-$98M-$89M-$81M-$812M
Value-$2.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-6%-2%-29%-15%-35%2%-2%-33%-22%-7%-45%
ROA--3%-11%-7%-12%2%1%-10%-8%-7%-7%
ROE--1%-16%-9%-20%2%-2%-21%-14%-4%-3%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-4.12-0.3-0.65-1.4643.3633.21-2.17-5.65-2.1-2.62
Debt over Equity0.030.030.020.050.170.150.120.170.180.320.41
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-148%-13%-7%-9%59%24%-43%-14%-17%-17%
Earnings YoY growth--20%1K%-50%106%-110%-199%989%-42%-72%0%
Equity YoY growth-6%-10%-5%-10%4%1%-7%-11%-2%-6%
FCF YoY growth--91%-1K%-1%35%-103%7%-2K%-63%369%-0%